Aurobindo Pharma, Shanghai LongJin sign deal to form JV in China
The joint venture is for development, manufacturing, marketing and sale of pharmaceutical products for China, excluding Taiwan, Hongkong and Macau, Aurobindo Pharma said in a filing to the BSE.
New Delhi: Drug firm Aurobindo Pharma on Friday said its arm Helix Healthcare B V, Netherlands has entered into an agreement with Chinese firm Shanghai LongJin Investment Company and Sveva Capitals, Hongkong to form a JV firm, Longxiang Pharma Taizhou Co Ltd in China.
The joint venture is for development, manufacturing, marketing and sale of pharmaceutical products for China, excluding Taiwan, Hongkong and Macau, Aurobindo Pharma said in a filing to the BSE.
While Helix will have 57 per cent shareholding in the JV, LongJin will have 40 per cent and Sveva will have 3 per cent shareholding, it added.
"Commencement of commercial production of JVC is expected during 2022-23," Aurobindo Pharma said.
Read Also: 2 dead, 1 injured after a fire engulfed Aurobindo Pharma power plant in Andhra Pradesh
Helix has the right to appoint three directors, while LongJin has the right to appoint two directors in JVC, it added.
Read Also: Aurobindo Pharma Q1 net profit up by 39.52 per cent to Rs 636 crore
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd